ATE365040T1 - Chirales dinapsolin - Google Patents

Chirales dinapsolin

Info

Publication number
ATE365040T1
ATE365040T1 AT02765964T AT02765964T ATE365040T1 AT E365040 T1 ATE365040 T1 AT E365040T1 AT 02765964 T AT02765964 T AT 02765964T AT 02765964 T AT02765964 T AT 02765964T AT E365040 T1 ATE365040 T1 AT E365040T1
Authority
AT
Austria
Prior art keywords
dinapsoline
chiral
napth
isoquinoline
tetrahydro
Prior art date
Application number
AT02765964T
Other languages
English (en)
Inventor
Sing-Yuen Sit
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Application granted granted Critical
Publication of ATE365040T1 publication Critical patent/ATE365040T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AT02765964T 2001-08-10 2002-08-08 Chirales dinapsolin ATE365040T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31161401P 2001-08-10 2001-08-10

Publications (1)

Publication Number Publication Date
ATE365040T1 true ATE365040T1 (de) 2007-07-15

Family

ID=23207674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02765964T ATE365040T1 (de) 2001-08-10 2002-08-08 Chirales dinapsolin

Country Status (6)

Country Link
US (1) US7091212B2 (de)
EP (1) EP1414457B1 (de)
JP (1) JP2005504758A (de)
AT (1) ATE365040T1 (de)
DE (1) DE60220800D1 (de)
WO (1) WO2003013532A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200225A (es) 2017-11-24 2020-07-25 H Lundbeck As Nuevos fármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
EP3972971A1 (de) 2019-05-21 2022-03-30 H. Lundbeck A/S Neue catecholamin-prodrugs zur verwendung in der behandlung von morbus parkinson
WO2020234277A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S Catecholamine carbamate prodrugs for use in the treatment of parkinson s disease
JP7641234B2 (ja) 2019-05-21 2025-03-06 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2020234276A1 (en) 2019-05-21 2020-11-26 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047536A (en) 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
AU4391493A (en) 1992-05-26 1993-12-30 Purdue Research Foundation Substituted-hexahydrobenzo(A)phenanthridines
JPH10502923A (ja) * 1994-07-15 1998-03-17 パーデュー・リサーチ・ファンデーション ジヒドレキシジンおよびその置換類似体の光学活性異性体
KR19990028636A (ko) 1995-07-05 1999-04-15 모토로라, 인크 컨포멀 전원 장치
WO1997006798A2 (en) 1995-08-12 1997-02-27 Smithkline Beecham Plc Pharmaceutical formulations
AU700688B2 (en) * 1995-08-18 1999-01-14 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands
KR20030027020A (ko) 2000-08-11 2003-04-03 펄듀 리서치 파운데이션 디나프솔린의 제조 공정

Also Published As

Publication number Publication date
EP1414457A1 (de) 2004-05-06
JP2005504758A (ja) 2005-02-17
WO2003013532A1 (en) 2003-02-20
US20040063741A1 (en) 2004-04-01
US7091212B2 (en) 2006-08-15
EP1414457B1 (de) 2007-06-20
EP1414457A4 (de) 2004-12-29
DE60220800D1 (de) 2007-08-02

Similar Documents

Publication Publication Date Title
CA2449729A1 (en) Prodrugs of gaba analogs, compositions and uses thereof
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
WO2001044272A3 (en) Daptomycin analogs as antibacterial agents
WO2001044271A3 (en) Daptomycin analogs and their use as antibacterial agents
SE0101675D0 (sv) Novel composition
EP2039699A3 (de) Extraktionsverfahren zur Reinigung von Sucralose
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
BR0207640A (pt) Composição farmacêutica oral de cefpodoxima proxetil
MA27769A1 (fr) Dérivées de 2-acylamino-4-phenylthiazole, leur préparation et leur application en thérapeutique
IS2750B (is) Leiðarafesting
SE0300119D0 (sv) Novel compounds
EP1420787B8 (de) Ascomycin enthaltende ophthalmische zubereitungen
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
GB0111186D0 (en) Novel compounds
SE9901077D0 (sv) Novel use
DE60220800D1 (de) Chirales dinapsolin
SE9801494D0 (sv) Novel use
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
MXPA06000636A (es) Formulaciones semi-solidas para la administracion oral de taxoides.
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
BRPI0410026A (pt) derivados de 3-amino-croman quinolina
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
SE0100297D0 (sv) New compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties